Skip to main content
SpringerLink
Log in

The APP Proteolytic System and Its Interactions with Dynamic Networks in Alzheimer’s Disease

  • Protocol
Book cover Systems Biology of Alzheimer's Disease

Part of the book series: Methods in Molecular Biology ((MIMB,volume 1303))

Abstract

Diseases of aging are often complex and multifactorial, involving many genetic and life course modifiers. Systems biology is becoming an essential tool to investigate disease initiation and disease progression. Alzheimer’s disease (AD) can be used as a case study to investigate the application of systems biology to complex disease. Here we describe approaches to capturing biological data, representing data in terms of networks and interpreting their meaning in relation to the human population. We highlight issues that remain to be addressed both in terms of modeling disease progression and in relating findings to the current understanding of human disease.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Protocol
USD 49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Tacutu R, Budovsky A, Yanai H, Fraifeld VE (2011) Molecular links between cellular senescence, longevity and age-related diseases—a systems biology perspective. Aging 3:1178–1191

    CAS  PubMed Central  PubMed  Google Scholar 

  2. Arendt T (2003) Synaptic plasticity and cell cycle activation in neurons are alternative effector pathways: the ‘Dr. Jekyll and Mr. Hyde concept’ of Alzheimer’s disease or the yin and yang of neuroplasticity. Prog Neurobiol 71:83–248

    PubMed  Google Scholar 

  3. Ray M, Ruan J, Zhang W (2008) Variations in the transcriptome of Alzheimer’s disease reveal molecular networks involved in cardiovascular diseases. Genome Biol 9:R148

    PubMed Central  PubMed  Google Scholar 

  4. Morris JC, Heyman A, Mohs RC et al (1989) The Consortium to Establish a Registry for Alzheimer’s Disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer’s disease. Neurology 39:1159–1165

    CAS  PubMed  Google Scholar 

  5. McKhann GM, Knopman DS, Chertkow H et al (2011) The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 7:263–269

    PubMed Central  PubMed  Google Scholar 

  6. Mirra SS, Heyman A, McKeel D et al (1991) The Consortium to Establish a Registry for Alzheimer’s Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer’s disease. Neurology 41:479–486

    CAS  PubMed  Google Scholar 

  7. Hyman BT, Phelps CH, Beach TG et al (2012) National Institute on Aging-Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease. Alzheimers Dement 8:1–13

    PubMed Central  PubMed  Google Scholar 

  8. Selkoe DJ (2001) Alzheimer’s disease: genes, proteins, and therapy. Physiol Rev 81:741–766

    CAS  PubMed  Google Scholar 

  9. Zekry D, Duyckaerts C, Belmin J et al (2003) Cerebral amyloid angiopathy in the elderly: vessel walls changes and relationship with dementia. Acta Neuropathol 10:367–373

    Google Scholar 

  10. Attems J, Jellinger K, Thal DR, Van Nostrand W (2011) Review: sporadic cerebral amyloid angiopathy. Neuropathol Appl Neurobiol 37:75–93

    CAS  PubMed  Google Scholar 

  11. Gatz M, Reynolds CA, Fratiglioni L et al (2006) Role of genes and environments for explaining Alzheimer disease. Arch Gen Psychiatry 63:168–174

    PubMed  Google Scholar 

  12. Pedersen NL, Gatz M, Berg S, Johansson B (2004) How heritable is Alzheimer’s disease late in life? Findings from Swedish twins. Ann Neurol 55:180–185

    PubMed  Google Scholar 

  13. Cedazo-Minguez A, Cowburn RF (2001) Apolipoprotein E: a major piece in the Alzheimer’s disease puzzle. J Cell Mol Med 5:254–266

    CAS  PubMed  Google Scholar 

  14. Harold D, Abraham R, Hollingworth P et al (2009) Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer’s disease. Nat Genet 41:1088–1093

    CAS  PubMed Central  PubMed  Google Scholar 

  15. Crehan H, Holton P, Wray S et al (2012) Complement receptor 1 (CR1) and Alzheimer’s disease. Immunobiology 217:244–250

    CAS  PubMed  Google Scholar 

  16. Bertram L, Tanzi RE (2012) The genetics of Alzheimer’s disease. Prog Mol Biol Transl Sci 107:79–100

    CAS  PubMed  Google Scholar 

  17. Schellenberg GD, Montine TJ (2012) The genetics and neuropathology of Alzheimer’s disease. Acta Neuropathol 124:305–323

    CAS  PubMed Central  PubMed  Google Scholar 

  18. Brayne C, Ince PG, Keage HA et al (2010) Education, the brain and dementia: neuroprotection or compensation? Brain 133:2210–2216

    PubMed  Google Scholar 

  19. Ma Q (2008) Beneficial effects of moderate voluntary physical exercise and its biological mechanisms on brain health. Neurosci Bull 24:265–270

    CAS  PubMed  Google Scholar 

  20. Mattson MP, Chan SL, Duan W (2002) Modification of brain aging and neurodegenerative disorders by genes, diet, and behavior. Physiol Rev 82:637–672

    CAS  PubMed  Google Scholar 

  21. Xuereb JH, Brayne C, Dufouil C et al (2000) Neuropathological findings in the very old. Results from the first 101 brains of a population-based longitudinal study of dementing disorders. Ann N Y Acad Sci 903:490–496

    CAS  PubMed  Google Scholar 

  22. Savva GM, Wharton SB, Ince PG et al (2009) Age, neuropathology, and dementia. N Engl J Med 360:2302–2309

    CAS  PubMed  Google Scholar 

  23. MRC-CFAS (2001) Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales. Neuropathology Group of the Medical Research Council Cognitive Function and Ageing Study (MRC CFAS). Lancet 357:169–175

    Google Scholar 

  24. Brayne C, Richardson K, Matthews FE et al (2009) Neuropathological correlates of dementia in over-80-year-old brain donors from the population-based Cambridge city over-75 s cohort (CC75C) study. J Alzheimers Dis 18:645–658

    PubMed  Google Scholar 

  25. Nakano T, Moore MJ, Wei F et al (2012) Molecular communication and networking: opportunities and challenges. IEEE Trans Nanobioscience 11:135–148

    PubMed  Google Scholar 

  26. Jensen ON (2006) Interpreting the protein language using proteomics. Nat Rev Mol Cell Biol 7:391–403

    CAS  PubMed  Google Scholar 

  27. Ratovitski T, Slunt HH, Thinakaran G et al (1997) Endoproteolytic processing and stabilization of wild-type and mutant presenilin. J Biol Chem 272:24536–24541

    CAS  PubMed  Google Scholar 

  28. da Costa CA, Ancolio K, Checler F (1999) C-terminal maturation fragments of presenilin 1 and 2 control secretion of APP alpha and A beta by human cells and are degraded by proteasome. Mol Med 5:160–168

    PubMed Central  PubMed  Google Scholar 

  29. Ogishima S, Mizuno S, Kikuchi M et al (2013) A map of Alzheimer’s disease-signaling pathways: a hope for drug target discovery. Clin Pharmacol Ther 93:399–401

    CAS  PubMed  Google Scholar 

  30. Kimberly WT, LaVoie MJ, Ostaszewski BL et al (2003) Gamma-secretase is a membrane protein complex comprised of presenilin, nicastrin, Aph-1, and Pen-2. Proc Natl Acad Sci U S A 100:6382–6387

    CAS  PubMed Central  PubMed  Google Scholar 

  31. Kimberly WT, Wolfe MS (2003) Identity and function of gamma-secretase. J Neurosci Res 74:353–360

    CAS  PubMed  Google Scholar 

  32. Kirkitadze MD, Condron MM, Teplow DB (2001) Identification and characterization of key kinetic intermediates in amyloid beta-protein fibrillogenesis. J Mol Biol 312:1103–1119

    CAS  PubMed  Google Scholar 

  33. Rubinstein A, Lyubchenko YL, Sherman S (2009) Dynamic properties of pH-dependent structural organization of the amyloidogenic beta-protein (1–40). Prion 3:31–43

    CAS  PubMed Central  PubMed  Google Scholar 

  34. Smith MA, Hirai K, Hsiao K et al (1998) Amyloid-beta deposition in Alzheimer transgenic mice is associated with oxidative stress. J Neurochem 70:2212–2215

    CAS  PubMed  Google Scholar 

  35. Berg JM, Tymoczko JL, Stryer L (2006) Biochemistry, 6th edn. W. H. Freeman and Company, New York, NY

    Google Scholar 

  36. Hunter S, Brayne C (2012) Relationships between the amyloid precursor protein and its various proteolytic fragments and neuronal systems. Alzheimers Res Ther 4:10

    CAS  PubMed Central  PubMed  Google Scholar 

  37. Perreau VM, Orchard S, Adlard PA et al (2010) A domain level interaction network of amyloid precursor protein and Abeta of Alzheimer’s disease. Proteomics 10:2377–2395

    CAS  PubMed  Google Scholar 

  38. Aranda B, Blankenburg H, Kerrien S et al (2011) PSICQUIC and PSISCORE: accessing and scoring molecular interactions. Nat Methods 8:528–529

    CAS  PubMed Central  PubMed  Google Scholar 

  39. Murphy D (2002) Gene expression studies using microarrays: principles, problems, and prospects. Adv Physiol Educ 26:256–270

    PubMed  Google Scholar 

  40. Baranzini SE (2004) Gene expression profiling in neurological disorders: toward a systems-level understanding of the brain. Neuromolecular Med 6:31–51

    CAS  PubMed  Google Scholar 

  41. Hu S, Xie Z, Qian J et al (2011) Functional protein microarray technology. Wiley Interdiscip Rev Syst Biol Med 3:255–268

    CAS  PubMed Central  PubMed  Google Scholar 

  42. Sutandy FX, Qian J, Chen CS, Zhu H (2013) Overview of protein microarrays. Curr Protoc Protein Sci. Editorial board, John E Coligan et al. Chapter 27: Unit 27.1. doi:10.1002/0471140864.ps2701s72

    Google Scholar 

  43. Kell DB (2010) Towards a unifying, systems biology understanding of large-scale cellular death and destruction caused by poorly liganded iron: Parkinson’s, Huntington’s, Alzheimer’s, prions, bactericides, chemical toxicology and others as examples. Arch Toxicol 84:825–889

    CAS  PubMed Central  PubMed  Google Scholar 

  44. Alberghina L, Colangelo AM (2006) The modular systems biology approach to investigate the control of apoptosis in Alzheimer’s disease neurodegeneration. BMC Neurosci 7(Suppl 1):S2

    PubMed Central  PubMed  Google Scholar 

  45. Soler-Lopez M, Zanzoni A, Lluis R et al (2011) Interactome mapping suggests new mechanistic details underlying Alzheimer’s disease. Genome Res 21:364–376

    CAS  PubMed Central  PubMed  Google Scholar 

  46. Suarez RK, Moyes CD (2012) Metabolism in the age of ‘omes’. J Exp Biol 215:2351–2357

    CAS  PubMed  Google Scholar 

  47. Braak H, Braak E (1991) Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 82:239–259

    CAS  PubMed  Google Scholar 

  48. Tamayev R, Zhou D, D’Adamio L (2009) The interactome of the amyloid beta precursor protein family members is shaped by phosphorylation of their intracellular domains. Mol Neurodegener 4:28

    PubMed Central  PubMed  Google Scholar 

  49. Raiteri M (2006) Functional pharmacology in human brain. Pharmacol Rev 58:162–193

    CAS  PubMed  Google Scholar 

  50. Kokjohn TA, Roher AE (2009) Amyloid precursor protein transgenic mouse models and Alzheimer’s disease: understanding the paradigms, limitations, and contributions. Alzheimers Dement 5:340–347

    CAS  PubMed Central  PubMed  Google Scholar 

  51. Miller JA, Horvath S, Geschwind DH (2010) Divergence of human and mouse brain transcriptome highlights Alzheimer disease pathways. Proc Natl Acad Sci U S A 107:12698–12703

    CAS  PubMed Central  PubMed  Google Scholar 

  52. Codita A, Winblad B, Mohammed AH (2006) Of mice and men: more neurobiology in dementia. Curr Opin Psychiatry 19:555–563

    PubMed  Google Scholar 

  53. Cohen RM, Rezai-Zadeh K, Weitz TM et al (2013) A transgenic Alzheimer rat with plaques, tau pathology, behavioral impairment, oligomeric abeta, and frank neuronal loss. J Neurosci 33:6245–6256

    CAS  PubMed Central  PubMed  Google Scholar 

  54. Barbero-Camps E, Fernandez A, Martinez L et al (2013) APP/PS1 mice overexpressing SREBP-2 exhibit combined Abeta accumulation and tau pathology underlying Alzheimer’s disease. Hum Mol Genet 22:3460–3476

    CAS  PubMed Central  PubMed  Google Scholar 

  55. Butterfield DA, Poon HF (2005) The senescence-accelerated prone mouse (SAMP8): a model of age-related cognitive decline with relevance to alterations of the gene expression and protein abnormalities in Alzheimer’s disease. Exp Gerontol 40:774–783

    CAS  PubMed  Google Scholar 

  56. Davidson YS, Raby S, Foulds PG et al (2011) TDP-43 pathological changes in early onset familial and sporadic Alzheimer’s disease, late onset alzheimer’s disease and Down’s syndrome: association with age, hippocampal sclerosis and clinical phenotype. Acta Neuropathol 122:703–713

    PubMed  Google Scholar 

  57. Keage HA, Ince PG, Matthews FE et al (2012) Impact of less common and “disregarded” neurodegenerative pathologies on dementia burden in a population-based cohort. J Alzheimers Dis 28:485–493

    CAS  PubMed  Google Scholar 

  58. Heber S, Herms J, Gajic V et al (2000) Mice with combined gene knock-outs reveal essential and partially redundant functions of amyloid precursor protein family members. J Neurosci 20:7951–7963

    CAS  PubMed  Google Scholar 

  59. De Strooper B, Annaert W (2000) Proteolytic processing and cell biological functions of the amyloid precursor protein. J Cell Sci 113:1857–1870

    PubMed  Google Scholar 

  60. Small DH, Clarris HL, Williamson TG et al (1999) Neurite-outgrowth regulating functions of the amyloid protein precursor of Alzheimer’s disease. J Alzheimers Dis 1:275–285

    CAS  PubMed  Google Scholar 

  61. Small DH, Nurcombe V, Reed G et al (1994) A heparin-binding domain in the amyloid protein precursor of Alzheimer’s disease is involved in the regulation of neurite outgrowth. J Neurosci 14:2117–2127

    CAS  PubMed  Google Scholar 

  62. Priller C, Bauer T, Mitteregger G et al (2006) Synapse formation and function is modulated by the amyloid precursor protein. J Neurosci 26:7212–7221

    CAS  PubMed  Google Scholar 

  63. Hoe HS, Rebeck GW (2008) Functional interactions of APP with the apoE receptor family. J Neurochem 106:2263–2271

    CAS  PubMed  Google Scholar 

  64. Okamoto T, Takeda S, Murayama Y, Ogata E, Nishimoto I (1995) Ligand-dependent G protein coupling function of amyloid transmembrane precursor. J Biol Chem 270:4205–4208

    CAS  PubMed  Google Scholar 

  65. Roncarati R, Sestan N, Scheinfeld MH et al (2002) The gamma-secretase-generated intracellular domain of beta-amyloid precursor protein binds Numb and inhibits notch signaling. Proc Natl Acad Sci U S A 99:7102–7107

    CAS  PubMed Central  PubMed  Google Scholar 

  66. Kogel D, Schomburg R, Schurmann T et al (2003) The amyloid precursor protein protects PC12 cells against endoplasmic reticulum stress-induced apoptosis. J Neurochem 87:248–256

    PubMed  Google Scholar 

  67. Georgopoulou N, McLaughlin M, McFarlane I, Breen KC (2001) The role of post-translational modification in beta-amyloid precursor protein processing. Biochem Soc Symp 67:23–36

    CAS  PubMed  Google Scholar 

  68. Bush AI, Pettingell WH Jr, de Paradis M et al (1994) The amyloid beta-protein precursor and its mammalian homologues. Evidence for a zinc-modulated heparin-binding superfamily. J Biol Chem 269:26618–26621

    CAS  PubMed  Google Scholar 

  69. Williamson TG, Nurcombe V, Beyreuther K et al (1995) Affinity purification of proteoglycans that bind to the amyloid protein precursor of Alzheimer’s disease. J Neurochem 65:2201–2208

    CAS  PubMed  Google Scholar 

  70. Hoe HS, Lee KJ, Carney RS et al (2009) Interaction of reelin with amyloid precursor protein promotes neurite outgrowth. J Neurosci 29:7459–7473

    CAS  PubMed Central  PubMed  Google Scholar 

  71. Hoe HS, Tran TS, Matsuoka Y et al (2006) DAB1 and Reelin effects on amyloid precursor protein and ApoE receptor 2 trafficking and processing. J Biol Chem 281:35176–35185

    CAS  PubMed  Google Scholar 

  72. Dahms SO, Hoefgen S, Roeser D et al (2010) Structure and biochemical analysis of the heparin-induced E1 dimer of the amyloid precursor protein. Proc Natl Acad Sci U S A 107:5381–5386

    CAS  PubMed Central  PubMed  Google Scholar 

  73. Fassa A, Mehta P, Efthimiopoulos S (2005) Notch 1 interacts with the amyloid precursor protein in a Numb-independent manner. J Neurosci Res 82:214–224

    CAS  PubMed  Google Scholar 

  74. McLoughlin DM, Miller CC (2008) The FE65 proteins and Alzheimer’s disease. J Neurosci Res 86:744–754

    CAS  PubMed  Google Scholar 

  75. Rebeck GW, Moir RD, Mui S et al (2001) Association of membrane-bound amyloid precursor protein APP with the apolipoprotein E receptor LRP. Brain Res Mol Brain Res 87:238–245

    CAS  PubMed  Google Scholar 

  76. Pietrzik CU, Busse T, Merriam DE et al (2002) The cytoplasmic domain of the LDL receptor-related protein regulates multiple steps in APP processing. EMBO J 21:5691–5700

    CAS  PubMed Central  PubMed  Google Scholar 

  77. Taru H, Suzuki T (2009) Regulation of the physiological function and metabolism of AbetaPP by AbetaPP binding proteins. J Alzheimers Dis 18:253–265

    CAS  PubMed  Google Scholar 

  78. Muresan Z, Muresan V (2005) c-Jun NH2-terminal kinase-interacting protein-3 facilitates phosphorylation and controls localization of amyloid-beta precursor protein. J Neurosci 25:3741–3751

    CAS  PubMed  Google Scholar 

  79. Suzuki T, Nakaya T (2008) Regulation of amyloid beta-protein precursor by phosphorylation and protein interactions. J Biol Chem 283:29633–29637

    CAS  PubMed Central  PubMed  Google Scholar 

  80. Lee MS, Kao SC, Lemere CA et al (2003) APP processing is regulated by cytoplasmic phosphorylation. J Cell Biol 163:83–95

    CAS  PubMed Central  PubMed  Google Scholar 

  81. Perez RG, Soriano S, Hayes JD et al (1999) Mutagenesis identifies new signals for beta-amyloid precursor protein endocytosis, turnover, and the generation of secreted fragments, including Abeta42. J Biol Chem 274:18851–18856

    CAS  PubMed  Google Scholar 

  82. Loerch PM, Lu T, Dakin KA et al (2008) Evolution of the aging brain transcriptome and synaptic regulation. PLoS One 3:e3329

    PubMed Central  PubMed  Google Scholar 

  83. Weidemann A, Konig G, Bunke D et al (1989) Identification, biogenesis, and localization of precursors of Alzheimer’s disease A4 amyloid protein. Cell 57:115–126

    CAS  PubMed  Google Scholar 

  84. Savage MJ, Trusko SP, Howland DS et al (1998) Turnover of amyloid beta-protein in mouse brain and acute reduction of its level by phorbol ester. J Neurosci 18:1743–1752

    CAS  PubMed  Google Scholar 

  85. Lyckman AW, Confaloni AM, Thinakaran G et al (1998) Post-translational processing and turnover kinetics of presynaptically targeted amyloid precursor superfamily proteins in the central nervous system. J Biol Chem 273:11100–11106

    CAS  PubMed  Google Scholar 

  86. Morales-Corraliza J, Mazzella MJ, Berger JD et al (2009) In vivo turnover of tau and APP metabolites in the brains of wild-type and Tg2576 mice: greater stability of sAPP in the beta-amyloid depositing mice. PLoS One 4:e7134

    PubMed Central  PubMed  Google Scholar 

  87. Wang R, Sweeney D, Gandy SE, Sisodia SS (1996) The profile of soluble amyloid beta protein in cultured cell media. Detection and quantification of amyloid beta protein and variants by immunoprecipitation-mass spectrometry. J Biol Chem 271:31894–31902

    CAS  PubMed  Google Scholar 

  88. Turner PR, O’Connor K, Tate WP, Abraham WC (2003) Roles of amyloid precursor protein and its fragments in regulating neural activity, plasticity and memory. Prog Neurobiol 70:1–32

    CAS  PubMed  Google Scholar 

  89. Selkoe DJ (1994) Normal and abnormal biology of the beta-amyloid precursor protein. Annu Rev Neurosci 17:489–517

    CAS  PubMed  Google Scholar 

  90. Pellegrini L, Passer BJ, Tabaton M et al (1999) Alternative, non-secretase processing of Alzheimer’s beta-amyloid precursor protein during apoptosis by caspase-6 and -8. J Biol Chem 274:21011–21016

    CAS  PubMed  Google Scholar 

  91. McPhie DL, Golde T, Eckman CB et al (2001) beta-Secretase cleavage of the amyloid precursor protein mediates neuronal apoptosis caused by familial Alzheimer’s disease mutations. Brain Res Mol Brain Res 97:103–113

    CAS  PubMed  Google Scholar 

  92. Cole SL, Vassar R (2007) The Alzheimer’s disease beta-secretase enzyme, BACE1. Mol Neurodegener 2:22

    PubMed Central  PubMed  Google Scholar 

  93. Sun X, He G, Song W (2006) BACE2, as a novel APP theta-secretase, is not responsible for the pathogenesis of Alzheimer’s disease in Down syndrome. FASEB J 20:1369–1376

    CAS  PubMed  Google Scholar 

  94. Slack BE, Ma LK, Seah CC (2001) Constitutive shedding of the amyloid precursor protein ectodomain is up-regulated by tumour necrosis factor-alpha converting enzyme. Biochem J 357:787–794

    CAS  PubMed Central  PubMed  Google Scholar 

  95. Allinson TM, Parkin ET, Turner AJ, Hooper NM (2003) ADAMs family members as amyloid precursor protein alpha-secretases. J Neurosci Res 74:342–352

    CAS  PubMed  Google Scholar 

  96. Yang P, Baker KA, Hagg T (2006) The ADAMs family: coordinators of nervous system development, plasticity and repair. Prog Neurobiol 79:73–94

    CAS  PubMed  Google Scholar 

  97. Talamagas AA, Efthimiopoulos S, Tsilibary EC et al (2007) Abeta(1–40)-induced secretion of matrix metalloproteinase-9 results in sAPPalpha release by association with cell surface APP. Neurobiol Dis 28:304–315

    CAS  PubMed  Google Scholar 

  98. Deuss M, Reiss K, Hartmann D (2008) Part-time alpha-secretases: the functional biology of ADAM 9, 10 and 17. Curr Alzheimer Res 5:187–201

    CAS  PubMed  Google Scholar 

  99. Hartmann D, Tournoy J, Saftig P et al (2001) Implication of APP secretases in notch signaling. J Mol Neurosci 17:171–181

    CAS  PubMed  Google Scholar 

  100. Edwards DR, Handsley MM, Pennington CJ (2008) The ADAM metalloproteinases. Mol Aspects Med 29:258–289

    CAS  PubMed  Google Scholar 

  101. Arribas J, Bech-Serra JJ, Santiago-Josefat B (2006) ADAMs, cell migration and cancer. Cancer Metastasis Rev 25:57–68

    PubMed  Google Scholar 

  102. Gralle M, Oliveira CL, Guerreiro LH et al (2006) Solution conformation and heparin-induced dimerization of the full-length extracellular domain of the human amyloid precursor protein. J Mol Biol 357:493–508

    CAS  PubMed  Google Scholar 

  103. Gralle M, Botelho MG, Wouters FS (2009) Neuroprotective secreted amyloid precursor protein acts by disrupting amyloid precursor protein dimers. J Biol Chem 284:15016–15025

    CAS  PubMed Central  PubMed  Google Scholar 

  104. Furukawa K, Sopher BL, Rydel RE et al (1996) Increased activity-regulating and neuroprotective efficacy of alpha-secretase-derived secreted amyloid precursor protein conferred by a C-terminal heparin-binding domain. J Neurochem 67:1882–1896

    CAS  PubMed  Google Scholar 

  105. Ghosal K, Vogt DL, Liang M et al (2009) Alzheimer’s disease-like pathological features in transgenic mice expressing the APP intracellular domain. Proc Natl Acad Sci U S A 106:18367–18372

    CAS  PubMed Central  PubMed  Google Scholar 

  106. Copanaki E, Chang S, Vlachos A et al (2010) sAPPalpha antagonizes dendritic degeneration and neuron death triggered by proteasomal stress. Mol Cell Neurosci 44:386–393

    CAS  PubMed  Google Scholar 

  107. Sennvik K, Fastbom J, Blomberg M et al (2000) Levels of alpha- and beta-secretase cleaved amyloid precursor protein in the cerebrospinal fluid of Alzheimer’s disease patients. Neurosci Lett 278:169–172

    CAS  PubMed  Google Scholar 

  108. Hook V, Schechter I, Demuth HU, Hook G (2008) Alternative pathways for production of beta-amyloid peptides of Alzheimer’s disease. Biol Chem 389:993–1006

    CAS  PubMed Central  PubMed  Google Scholar 

  109. Sun X, Wang Y, Qing H et al (2005) Distinct transcriptional regulation and function of the human BACE2 and BACE1 genes. FASEB J 19:739–749

    CAS  PubMed  Google Scholar 

  110. Li Q, Sudhof TC (2004) Cleavage of amyloid-beta precursor protein and amyloid-beta precursor-like protein by BACE 1. J Biol Chem 279:10542–10550

    CAS  PubMed  Google Scholar 

  111. Lichtenthaler SF, Dominguez DI, Westmeyer GG et al (2003) The cell adhesion protein P-selectin glycoprotein ligand-1 is a substrate for the aspartyl protease BACE1. J Biol Chem 278:48713–48719

    CAS  PubMed  Google Scholar 

  112. Scholefield Z, Yates EA, Wayne G et al (2003) Heparan sulfate regulates amyloid precursor protein processing by BACE1, the Alzheimer’s beta-secretase. J Cell Biol 163:97–107

    CAS  PubMed Central  PubMed  Google Scholar 

  113. Nikolaev A, McLaughlin T, O’Leary DD, Tessier-Lavigne M (2009) APP binds DR6 to trigger axon pruning and neuron death via distinct caspases. Nature 457:981–989

    CAS  PubMed Central  PubMed  Google Scholar 

  114. Vetrivel KS, Zhang YW, Xu H, Thinakaran G (2006) Pathological and physiological functions of presenilins. Mol Neurodegener 1:4

    PubMed Central  PubMed  Google Scholar 

  115. Selkoe DJ (1994) Cell biology of the amyloid beta-protein precursor and the mechanism of Alzheimer’s disease. Annu Rev Cell Biol 10:373–403

    CAS  PubMed  Google Scholar 

  116. Zhao G, Cui MZ, Mao G et al (2005) gamma-Cleavage is dependent on zeta-cleavage during the proteolytic processing of amyloid precursor protein within its transmembrane domain. J Biol Chem 280:37689–37697

    CAS  PubMed  Google Scholar 

  117. Qi-Takahara Y, Morishima-Kawashima M, Tanimura Y et al (2005) Longer forms of amyloid beta protein: implications for the mechanism of intramembrane cleavage by gamma-secretase. J Neurosci 25:436–445

    CAS  PubMed  Google Scholar 

  118. Okochi M, Tagami S, Yanagida K et al (2013) Gamma-secretase modulators and presenilin 1 mutants act differently on presenilin/gamma-secretase function to cleave Abeta42 and Abeta43. Cell Rep 3:42–51

    CAS  PubMed  Google Scholar 

  119. Chen F, Hasegawa H, Schmitt-Ulms G et al (2006) TMP21 is a presenilin complex component that modulates gamma-secretase but not epsilon-secretase activity. Nature 440:1208–1212

    CAS  PubMed  Google Scholar 

  120. Lleo A, Waldron E, von Arnim CA et al (2005) Low density lipoprotein receptor-related protein (LRP) interacts with presenilin 1 and is a competitive substrate of the amyloid precursor protein (APP) for gamma-secretase. J Biol Chem 280:27303–27309

    CAS  PubMed  Google Scholar 

  121. von Arnim CA, Kinoshita A, Peltan ID et al (2005) The low density lipoprotein receptor-related protein (LRP) is a novel beta-secretase (BACE1) substrate. J Biol Chem 280:17777–17785

    Google Scholar 

  122. Shen J, Kelleher RJ 3rd (2007) The presenilin hypothesis of Alzheimer’s disease: evidence for a loss-of-function pathogenic mechanism. Proc Natl Acad Sci U S A 104:403–409

    CAS  PubMed Central  PubMed  Google Scholar 

  123. Uemura K, Kuzuya A, Shimohama S (2004) Protein trafficking and Alzheimer’s disease. Curr Alzheimer Res 1:1–10

    CAS  PubMed  Google Scholar 

  124. Boo JH, Sohn JH, Kim JE et al (2008) Rac1 changes the substrate specificity of gamma-secretase between amyloid precursor protein and Notch1. Biochem Biophys Res Commun 372:913–917

    CAS  PubMed  Google Scholar 

  125. Liu Y, Zhang YW, Wang X et al (2009) Intracellular trafficking of presenilin 1 is regulated by beta-amyloid precursor protein and phospholipase D1. J Biol Chem 284:12145–12152

    CAS  PubMed Central  PubMed  Google Scholar 

  126. Vetrivel KS, Cheng H, Kim SH et al (2005) Spatial segregation of gamma-secretase and substrates in distinct membrane domains. J Biol Chem 280:25892–25900

    CAS  PubMed Central  PubMed  Google Scholar 

  127. Bitan G, Teplow DB (2004) Rapid photochemical cross-linking–a new tool for studies of metastable, amyloidogenic protein assemblies. Acc Chem Res 37:357–364

    CAS  PubMed  Google Scholar 

  128. Pearson HA, Peers C (2006) Physiological roles for amyloid beta peptides. J Physiol 575:5–10

    CAS  PubMed Central  PubMed  Google Scholar 

  129. Saito T, Suemoto T, Brouwers N et al (2011) Potent amyloidogenicity and pathogenicity of Abeta43. Nat Neurosci 14:1023–1032

    CAS  PubMed  Google Scholar 

  130. Miravalle L, Tokuda T, Chiarle R et al (2000) Substitutions at codon 22 of Alzheimer’s abeta peptide induce diverse conformational changes and apoptotic effects in human cerebral endothelial cells. J Biol Chem 275:27110–27116

    CAS  PubMed  Google Scholar 

  131. Murakami K, Irie K, Morimoto A et al (2002) Synthesis, aggregation, neurotoxicity, and secondary structure of various A beta 1–42 mutants of familial Alzheimer’s disease at positions 21–23. Biochem Biophys Res Commun 294:5–10

    CAS  PubMed  Google Scholar 

  132. Kakio A, Yano Y, Takai D et al (2004) Interaction between amyloid beta-protein aggregates and membranes. J Pept Sci 10:612–621

    CAS  PubMed  Google Scholar 

  133. Klug GM, Losic D, Subasinghe SS et al (2003) Beta-amyloid protein oligomers induced by metal ions and acid pH are distinct from those generated by slow spontaneous ageing at neutral pH. Eur J Biochem 270:4282–4293

    CAS  PubMed  Google Scholar 

  134. Zhao JH, Liu HL, Liu YF et al (2009) Molecular dynamics simulations to investigate the aggregation behaviors of the Abeta(17–42) oligomers. J Biomol Struct Dyn 26:481–490

    CAS  PubMed  Google Scholar 

  135. Zheng J, Jang H, Ma B et al (2007) Modeling the Alzheimer Abeta17-42 fibril architecture: tight intermolecular sheet-sheet association and intramolecular hydrated cavities. Biophys J 93:3046–3057

    CAS  PubMed Central  PubMed  Google Scholar 

  136. Miller Y, Ma B, Nussinov R (2009) Polymorphism of Alzheimer’s Abeta17-42 (p3) oligomers: the importance of the turn location and its conformation. Biophys J 97:1168–1177

    CAS  PubMed Central  PubMed  Google Scholar 

  137. Thal DR, Sassin I, Schultz C et al (1999) Fleecy amyloid deposits in the internal layers of the human entorhinal cortex are comprised of N-terminal truncated fragments of Abeta. J Neuropathol Exp Neurol 58:210–216

    CAS  PubMed  Google Scholar 

  138. Liu R, McAllister C, Lyubchenko Y, Sierks MR (2004) Residues 17–20 and 30–35 of beta-amyloid play critical roles in aggregation. J Neurosci Res 75:162–171

    CAS  PubMed  Google Scholar 

  139. Wei W, Norton DD, Wang X, Kusiak JW (2002) Abeta 17–42 in Alzheimer’s disease activates JNK and caspase-8 leading to neuronal apoptosis. Brain 125:2036–2043

    PubMed  Google Scholar 

  140. White AR, Maher F, Brazier MW et al (2003) Diverse fibrillar peptides directly bind the Alzheimer’s amyloid precursor protein and amyloid precursor-like protein 2 resulting in cellular accumulation. Brain Res 966:231–244

    CAS  PubMed  Google Scholar 

  141. Beckman M, Holsinger RM, Small DH (2006) Heparin activates beta-secretase (BACE1) of Alzheimer’s disease and increases autocatalysis of the enzyme. Biochemistry 45:6703–6714

    CAS  PubMed  Google Scholar 

  142. Bame KJ, Danda J, Hassall A, Tumova S (1997) Abeta(1–40) prevents heparanase-catalyzed degradation of heparan sulfate glycosaminoglycans and proteoglycans in vitro. A role for heparan sulfate proteoglycan turnover in Alzheimer’s disease. J Biol Chem 272:17005–17011

    CAS  PubMed  Google Scholar 

  143. Klajnert B, Cortijo-Arellano M, Bryszewska M, Cladera J (2006) Influence of heparin and dendrimers on the aggregation of two amyloid peptides related to Alzheimer’s and prion diseases. Biochem Biophys Res Commun 339:577–582

    CAS  PubMed  Google Scholar 

  144. Bergamaschini L, Donarini C, Rossi E et al (2002) Heparin attenuates cytotoxic and inflammatory activity of Alzheimer amyloid-beta in vitro. Neurobiol Aging 23:531–536

    CAS  PubMed  Google Scholar 

  145. Winkler K, Scharnagl H, Tisljar U et al (1999) Competition of Abeta amyloid peptide and apolipoprotein E for receptor-mediated endocytosis. J Lipid Res 40:447–455

    CAS  PubMed  Google Scholar 

  146. Benilova I, Karran E, De Strooper B (2012) The toxic Abeta oligomer and Alzheimer’s disease: an emperor in need of clothes. Nat Neurosci 15:349–357

    CAS  PubMed  Google Scholar 

  147. Svedruzic ZM, Popovic K, Smoljan I, Sendula-Jengic V (2012) Modulation of gamma-secretase activity by multiple enzyme-substrate interactions: implications in pathogenesis of Alzheimer’s disease. PLoS One 7:e32293

    CAS  PubMed Central  PubMed  Google Scholar 

  148. Yan Y, Wang C (2006) Abeta42 is more rigid than Abeta40 at the C terminus: implications for Abeta aggregation and toxicity. J Mol Biol 364:853–862

    CAS  PubMed  Google Scholar 

  149. Lee DH, Wang HY (2003) Differential physiologic responses of alpha7 nicotinic acetylcholine receptors to beta-amyloid1-40 and beta-amyloid1-42. J Neurobiol 55:25–30

    CAS  PubMed  Google Scholar 

  150. Zou K, Kim D, Kakio A et al (2003) Amyloid beta-protein (Abeta)1-40 protects neurons from damage induced by Abeta1-42 in culture and in rat brain. J Neurochem 87:609–619

    CAS  PubMed  Google Scholar 

  151. Parameshwaran K, Sims C, Kanju P et al (2007) Amyloid beta-peptide Abeta(1–42) but not Abeta(1–40) attenuates synaptic AMPA receptor function. Synapse 61:367–374

    CAS  PubMed  Google Scholar 

  152. Chavez-Gutierrez L, Bammens L, Benilova I et al (2012) The mechanism of gamma-secretase dysfunction in familial Alzheimer disease. EMBO J 31:2261–2274

    CAS  PubMed Central  PubMed  Google Scholar 

  153. Svedruzic ZM, Popovic K, Sendula-Jengic V (2013) Modulators of gamma-secretase activity can facilitate the toxic side-effects and pathogenesis of Alzheimer’s disease. PLoS One 8:e50759

    CAS  PubMed Central  PubMed  Google Scholar 

  154. Orchard S, Salwinski L, Kerrien S et al (2007) The minimum information required for reporting a molecular interaction experiment (MIMIx). Nat Biotechnnol 25:894–898

    CAS  Google Scholar 

  155. Taylor CF, Paton NW, Lilley KS et al (2007) The minimum information about a proteomics experiment (MIAPE). Nat Biotechnol 25:887–893

    CAS  PubMed  Google Scholar 

  156. Kasabov N (2010) To spike or not to spike: a probabilistic spiking neuron model. Neural Netw 23:16–19

    PubMed  Google Scholar 

  157. Kasabov N, Schliebs R, Kojima H (2011) Probabilistic computational neurogenetic modeling: from cognitive systems to Alzheimer’s disease. IEEE Trans Auton Ment Dev 3:300–311. doi:10.1109/TAMD.2011.2159839

    Google Scholar 

  158. Kasabov N, Benuskova L, Wysoski SG (2005) Biologically plausible computational neurogenetic models: modeling the interaction between genes, neurons and neural networks. J Comput Theor Nanosci 2:569–573

    CAS  Google Scholar 

  159. Habeck C, Foster NL, Perneczky R et al (2008) Multivariate and univariate neuroimaging biomarkers of Alzheimer’s disease. Neuroimage 40:1503–1515

    PubMed Central  PubMed  Google Scholar 

  160. Haense C, Buerger K, Kalbe E et al (2008) CSF total and phosphorylated tau protein, regional glucose metabolism and dementia severity in Alzheimer’s disease. Eur J Neurol 15:1155–1162

    CAS  PubMed  Google Scholar 

  161. Desikan RS, Cabral HJ, Hess CP et al (2009) Automated MRI measures identify individuals with mild cognitive impairment and Alzheimer’s disease. Brain 132:2048–2057

    PubMed Central  PubMed  Google Scholar 

  162. Wang H, Nie F, Huang H et al (2011) Identifying AD-sensitive and cognition-relevant imaging biomarkers via joint classification and regression. Med Image Comput Comput Assist Interv 14:115–123

    PubMed Central  PubMed  Google Scholar 

  163. Cui Y, Liu B, Luo S et al (2011) Identification of conversion from mild cognitive impairment to Alzheimer’s disease using multivariate predictors. PLoS One 6:e21896

    CAS  PubMed Central  PubMed  Google Scholar 

  164. Hinrichs C, Singh V, Xu G, Johnson SC (2011) Predictive markers for AD in a multi-modality framework: an analysis of MCI progression in the ADNI population. Neuroimage 55:574–589

    PubMed Central  PubMed  Google Scholar 

  165. Zhang D, Wang Y, Zhou L et al (2011) Multimodal classification of Alzheimer’s disease and mild cognitive impairment. Neuroimage 55:856–867

    PubMed Central  PubMed  Google Scholar 

  166. Gray KR, Aljabar P, Heckemann RA et al (2013) Random forest-based similarity measures for multi-modal classification of Alzheimer’s disease. Neuroimage 65:167–175

    PubMed  Google Scholar 

  167. Van Essen DC, Ugurbil K (2012) The future of the human connectome. Neuroimage 62:1299–1310

    PubMed Central  PubMed  Google Scholar 

  168. Castellani RJ, Perry G (2012) Pathogenesis and disease-modifying therapy in Alzheimer’s disease: the flat line of progress. Arch Med Res 43:694–698

    CAS  PubMed  Google Scholar 

  169. Carrillo MC, Rowe CC, Szoeke C et al (2013) Research and standardization in Alzheimer’s trials: reaching international consensus. Alzheimers Dement 9:160–168

    PubMed  Google Scholar 

  170. Stern Y (2012) Cognitive reserve in ageing and Alzheimer’s disease. Lancet Neurol 11:1006–1012

    PubMed Central  PubMed  Google Scholar 

Download references

Acknowledgements

The authors were supported by the Cambridgeshire and Peterborough Collaboration for Leadership in Applied Health Research and Care (CLAHRC).

Author information

Authors and Affiliations

  1. Department of Public Health and Primary Care, Institute of Public Health, University of Cambridge School of Clinical Medicine, Forvie Site, Cambridge Biomedical Campus, Box 113, Cambridge, CB2 0SP, UK

    Sally Hunter, Steven Martin & Carol Brayne

Authors
  1. Sally Hunter
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Steven Martin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Carol Brayne
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sally Hunter .

Editor information

Editors and Affiliations

  1. Department of Biochemistry & Cambridge Systems Biology Centre, University of Cambridge, Cambridge, United Kingdom

    Juan I. Castrillo

  2. Department of Biochemistry & Cambridge Systems Biology Centre, University of Cambridge, Cambridge, United Kingdom

    Stephen G. Oliver

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer Science+Business Media New York

About this protocol

Cite this protocol

Hunter, S., Martin, S., Brayne, C. (2016). The APP Proteolytic System and Its Interactions with Dynamic Networks in Alzheimer’s Disease. In: Castrillo, J., Oliver, S. (eds) Systems Biology of Alzheimer's Disease. Methods in Molecular Biology, vol 1303. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-2627-5_3

Download citation

  • DOI: https://doi.org/10.1007/978-1-4939-2627-5_3

  • Publisher Name: Humana Press, New York, NY

  • Print ISBN: 978-1-4939-2626-8

  • Online ISBN: 978-1-4939-2627-5

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics

Search

Navigation